Lluís Masana Articles

What is the take home message from ODYSSEY Outcomes regarding the role of LDL cholesterol in CVD prevention?

REVEAL Study. Should we welcome a new lipid lowering drug family?

The significant and positive results obtained by REVEAL (Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification study) (1) are good news. These data show that we have a new lipid modifying drug, that by significantly reducing atherogenic non-high-density lipoprotein (HDL) cholesterol, decreases major cardiovascular…

‘High-intensity cholesterol-lowering therapy’ versus ‘high-intensity statin therapy’

Is it time to change the paradigm? Recent guidelines come under scrutiny from Professor Luis Masana, University Rovira and Virgili, Reus-Tarragona, Spain The 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines on cholesterol management for cardiovascular disease prevention identified four groups of patients that…

Weighing the cost versus benefit of PCSK9-targeted therapy

PCSK9 inhibitors are the most important advance in cholesterol lowering treatments since the discovery of statin drugs, says Spanish vascular disease researcher, Professor Lluís Masana.

High cholesterol: an unmet need

Health authorities are failing to recognise that most patients do not achieve the cholesterol levels needed to prevent cardiovascular disease. Professor Lluís Masana says this must become a public health priority.

How can we optimise PCSK9-targeted therapies?

Highly relevant to these discussions was how to optimise the use of PCSK9-targeted therapies, discussed from both European (Professor Luís Masana, University Rovira and Virgili, Reus-Tarragona, Spain) and North American (Professor Henry Ginsberg, Columbia University, New York, USA) perspectives, from the guidelines perspectives. There are…